| Methods |
Four‐week randomised, double‐blind study |
| Participants |
In‐ and outpatients fulfilling DSM‐III‐R criteria for major depressive disorder, with a score of at least 17 on the Hamilton Rating Scale for Depression (HDRS).
Age range: 18‐64 years
Exclusion criteria: not specified. Patients were physical healthy, non obese and did not have DSM‐III‐R axis 2 disorders. |
| Interventions |
Fluoxetine: 7 participants
Amitryptyline: 9 participants
Fluoxetine dose: 20 mg/day
Amitryptyline dose: 250 mg/day |
| Outcomes |
Primary outcome: HDRS |
| Notes |
Funding: unclear |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Random sequence generation (selection bias) |
Unclear risk |
Randomised, no further information |
| Allocation concealment (selection bias) |
Unclear risk |
No information provided |
| Blinding (performance bias and detection bias)
All outcomes |
Unclear risk |
No information provided |
| Blinding of participants and personnel (performance bias)
All outcomes |
Unclear risk |
No information provided |
| Blinding of outcome assessment (detection bias)
All outcomes |
Unclear risk |
No information provided |
| Incomplete outcome data (attrition bias)
All outcomes |
Low risk |
End point scores reported for each patient. All patients complete the study |
| Selective reporting (reporting bias) |
Low risk |
Side effects not reported |
| Other bias |
Unclear risk |
Funding: unclear |
